prezentace aplikace powerpoint - virology...
TRANSCRIPT
![Page 1: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/1.jpg)
Clinical considerations in switching antiretroviral therapy
David JilichDepartment of Infctious Diseases, 1st Faculty of Medicine,
Charles University in Prague and Na Bulovce Hospital
4th CEE Meeting on Viral Hepatitis and HIV
October 11, 2018
![Page 2: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/2.jpg)
Dislosures
• DJ has recieved honoraria for Advisory Board participation by GileadSciences, GSK ViiV and travel grants by Gilead Sciences
![Page 3: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/3.jpg)
http://www.eacsociety.org/files/guidelines_9.0-english.pdf
![Page 4: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/4.jpg)
Reasons for switching
• toxicity
• intolerance
• DDI´s
• comorbidities (e.g. liver or renal failure)
• aging/risk factors (cardiovascular, diabetes, etc.)
• incovenience/simplification (pill burden, bid)
• patient´s wish/preference (STR)
• specific populations (drug users, pregnant women, etc.)
![Page 5: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/5.jpg)
Reasons for switching (DORIVIR Study)
42,3
27,8
17,3
12,5
toxicity inconvenience DDI´s other
n=104
Palacios et al. 2018
%
%
%
%
![Page 6: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/6.jpg)
TDF vs. TAF
† T1/2 based on in-vitro plasma data1. Lee W, et al. Antimicr Agents Chemo 2005;49(5):1898–906; 2. Birkus G, et al. Antimicr Agents Chemo 2007;51(2):543–50; 3. Babusis
D, et al. Mol Pharm 2013;10(2):459–66; 4. Ruane P, et al. J Acquir Immune Defic Syndr 2013; 63:449–5; 5. Sax P, et al. JAIDS 2014;67(1):52–8; 6. Sax P, et al. Lancet 2015 [Epub
ahead of print]
HIV TARGET CELL
AMIDATE
ESTER
DIANION
GI TRACT
Tenofovir
alafenamide
(TAF)
Tenofovir
disoproxil
fumarate
(TDF)
Tenofovir
(TFV) Parent
Nucleotide
T1/2 = 90 min†
T1/2 = 0.4 min†
PLASMA
TAF10mg
TDF 300 mg
TFV
TFV
TFV
91% lower TFV levels minimize renal and bone effects while maintaining high potency for suppressing HIV
TFV HIV
![Page 7: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/7.jpg)
Studies 104 & 111 (w144)
* p-values calculated using 2-sided Wilcoxon rank-sum test to compare treatment groups.
Arribas J et al. CROI 2017. Seattle, WA. Poster #453;
-24
-20
-16
-12
-8
-4
0
4
8
Week
Me
dia
n (I
QR
) ch
ange
fr
om
BL
(mL/
min
)
eGFR
-1.6
-7.7
-2.0
-7.7
-6.2
-11.2
-6.0
-10.5
0 12 24 48 96 144
E/C/F/TDFE/C/F/TAFBL, mL/min117.0113.9
p <0.001
![Page 8: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/8.jpg)
Intolerance
Raffi F et al. J Antimicrob Chemother 2014; 69: 1742–1747
![Page 9: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/9.jpg)
Intolerance
Raffi F et al. J Antimicrob Chemother 2014; 69: 1742–1747
![Page 10: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/10.jpg)
Lipid profiles in 48w (DOR vs. DRV/r) 30.8.2018
Molina et al. CROI 2017 Abstract 45LB
![Page 11: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/11.jpg)
DDI´s
● ▪ ◊
RAL 0 26 630
DTG 4 38 614
EVG/c 12 262 382
www.hiv-druginteractions.org
![Page 12: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/12.jpg)
Cobicistat vs. RitonavirCobicistat Ritonavir
Chemical structure
Enzymatic inhibition CYP3A4CYP2D6 (slabá)
P-gp
CYP3A4CYP2C8CYP2C9CYP2D6
P-gp
Enzymatic induction None CYP2B6CYP2C9
CYP2C19UGT1A4
P-gp
Anti-HIV activity No Yes
Co-administration withother antiretrovirals
Yes Yes with limitations
Influence of lab markers Increases serum creatinine concentration without decreasing renal function, increases lipids
Increases serum lipids
CYP = cytochrome P450; P-gp = P-glycoprotein; UGT = uridine 5’-diphosphoglucuronosyltransferase.
Shah B, et al. Pharmacotherapy. 2013;33(10):1107-1016.
![Page 13: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/13.jpg)
Non-boosted agents
13
BIC
RAL EVG
DTG
![Page 14: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/14.jpg)
DDI´s in HIV/HCV co-infected persons
www-hep-druginteractions.org
![Page 15: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/15.jpg)
Study 1717 (Platelet Substudy)
Phase 3, randomised, double-blinded, active-controlled study
Week 0 9648
n=280
n=276
1:1
ABC/3TC + Third Agent
• HIV-1 RNA <50 c/mL for ≥6 months
• No CD4 criteria
• Estimated CrCL ≥50 mL/min
• No single-tablet regimen allowed
TAF/FTC QD
Continue Third Agent
ABC/3TC QD
Continue Third Agent
Platelet Substudy (n=61)
From 4 sites in Dublin and London
120 4
12
Objectives of platelet substudy and gGPVI analysis:• Measure platelet reactivity using aggregometry at baseline, Week 4, Week 121
• Collagen, TRAP, ADP, epinephrine, arachidonic acid• Measure platelet surface markers at baseline and Week 121
• GPVI, CD42b [GP1bA], P-selectin [CD62P]• Measure soluble GPVI through Week 48 (whole Study 1717 population, n=545)2
ADP, adenosine diphosphate; GPVI, glycoprotein VI; TRAP, thrombin receptor-activating peptide
1. Mallon P, et al. CROI 2018. Boston, MA. Oral 802. Mallon P, et al. CROI 2018. Boston, MA. Poster 677LB
sGPVI (n=545)
![Page 16: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/16.jpg)
Solubile GPVI (Study 1717)
In TAF/FTC arm , solubile GPVI significantly increases within 48 weeks
0
1 0
2 0
3 0
4 0
5 0
4 1 2 2 4 4 80
Prů
měr
ná
% z
měn
aso
lub
ilníh
oG
PV
I
Week
TAF/FTC ABC/3TC
Mallon P, et al. CROI 2018. Boston, MA. Poster 677LB
268 261 259 252 229TAF/FTC, n=267 259 259 255 243ABC/3TC, n=
![Page 17: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/17.jpg)
Pill burden (past vs. present)
![Page 18: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/18.jpg)
Pill size (plays a role…)
E/C/F/TAF (1082 mg)
DTG/ABC/3TC (1750 mg)
B/F/TAF (721 mg)
![Page 19: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/19.jpg)
Dual therapy (in Europe)
0
2
4
6
8
10
12
14
16
18
EU5 France Germany Italy Spain UK
Chart Title
2013 2017
IPSOS, HIV Heathy Living 2018, poster 006
![Page 20: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/20.jpg)
Female populations specifics
www.hiv-druginteractions.org
![Page 21: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/21.jpg)
Female populations specifics
www.hiv-druginteractions.org
![Page 22: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/22.jpg)
Female population specifics
https://aidsinfo.nih.gov/news/2109/recommendations-regarding-the-use-of-dolutegravir-in-adults-and-adolescents-with-hiv-who-are-pregnant-or-of-child-bearing-potential
http://www.eacsociety.org/files/guidelines_9.0-english.pdf
![Page 23: Prezentace aplikace PowerPoint - Virology Educationregist2.virology-education.com/presentations/2018/4CEE/12_Jilich.pdf · Clinical considerations in switching antiretroviral therapy](https://reader031.vdocuments.mx/reader031/viewer/2022011819/5e962f9fe30096516256f4e0/html5/thumbnails/23.jpg)
Summary
Switch strategy should be:
• individualized
• optimalized